FY2027 EPS Estimates for Kura Oncology Cut by HC Wainwright

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at HC Wainwright lowered their FY2027 earnings estimates for Kura Oncology in a report released on Friday, June 12th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($2.82) for the year, down from their previous estimate of ($2.70). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.47) per share. HC Wainwright also issued estimates for Kura Oncology’s FY2028 earnings at ($2.44) EPS and FY2029 earnings at ($2.25) EPS.

Several other equities research analysts have also recently issued reports on the stock. Wells Fargo & Company set a $24.00 target price on shares of Kura Oncology in a research report on Thursday, June 4th. Lake Street Capital initiated coverage on shares of Kura Oncology in a research report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 target price on the stock. Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. CLSA set a $24.00 target price on shares of Kura Oncology in a research report on Thursday, June 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.46.

Kura Oncology Price Performance

KURA opened at $9.54 on Tuesday. The company’s 50 day simple moving average is $9.33 and its 200 day simple moving average is $9.29. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15. Kura Oncology has a 1 year low of $5.45 and a 1 year high of $12.49. The stock has a market capitalization of $846.87 million, a PE ratio of -2.85 and a beta of 0.36.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The business had revenue of $18.27 million for the quarter, compared to analysts’ expectations of $25.97 million.

Institutional Trading of Kura Oncology

Large investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc raised its position in Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after buying an additional 3,072 shares during the period. Allworth Financial LP grew its stake in shares of Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after buying an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after buying an additional 3,769 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after buying an additional 9,958 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.